

4 November 2025

## **ASX Announcement**

### **Contained fire event at R&D facility**

Polynovo advises that a fire occurred at the Company's R&D facility this morning. The fire affected only a small section of the facility and was quickly contained by the fire brigade. The building was unoccupied at the time, and no one was injured. The cause of the fire is being investigated and insurers have been notified.

The R&D facility is a standalone building, and the fire had no effect on the Company's manufacturing capacity or inventory. As a result, we do not anticipate the incident will have any impact on the Company's sales.

Further to this we do not anticipate that the damage from the fire will impact upon R&D activities, as we have two separate R&D facilities, with the remaining facility entirely unaffected.

This announcement has been authorised by the Company Secretary Jan Gielen.

#### **About PolyNovo®**

PolyNovo is a disruptive medical technology company, based in Melbourne, Australia. Its products simplify management of acute complex wounds, redefining healing with meaningfully differentiated patient outcomes across multiple wound etiologies. After treating 84,000+ patients across 46 countries, the company is investing in growth with new products, indications, and markets. For more information see [polynovo.com](https://polynovo.com).

#### **About NovoSorb®**

NovoSorb BTM is a dermal scaffold for the regeneration of the dermis when lost through surgery, trauma or burn. NovoSorb is a novel range of bio-resorbable polymers that can be produced in many formats including film, fibre, foam, and coatings. NovoSorb's unique properties provide excellent biocompatibility, control over physical properties, and a programmable bio-resorption profile.

### **About NovoSorb MTX<sup>®</sup>**

NovoSorb MTX leverages the technology platform underpinning the clinical success of NovoSorb BTM, but without a sealing membrane, and is designed to support natural wound healing, especially for wounds that are highly exudative or those with an uneven wound bed. The product was developed to satisfy clinician demand for a product for use in indications where the sealing membrane is not required.

### **About Beta Cell**

PolyNovo is supplying NovoSorb BTM to Beta Cell Technologies Pty Ltd for clinical trial purposes following positive results of the First in Man proof of concept study. The study involved transplanting human pancreatic islets into an alternative neovascularised site within the skin for 3 trial participants using NovoSorb BTM to create a cell supporting vascular bed.

For personal use